Gland Pharma Ltd fundamental analysis highlights key financial metrics including a market capitalization of ₹32,307.81 crores, a P/E ratio of 42.4, a debt-to-equity ratio of 4.27 and a return on equity of 9.26%, reflecting the company’s financial health and market valuation.
Gland Pharma Ltd Overview
Gland Pharma Ltd is a generic injectable-focused pharmaceutical company specializing in sterile injectables, oncology and ophthalmology. It operates in the healthcare sector, offering development and manufacturing across various delivery systems.
With a market capitalization of ₹32,307.81 crores, the stock is listed on the Indian stock exchanges. The current price is 13.26% away from its 52-week high and 32.94% above its 52-week low.
Gland Pharma Financial Results
Gland Pharma Ltd’s financial data shows strong growth, with consolidated sales reaching ₹5,665 crores in FY 24. The company continues to expand its assets and maintain a stable financial position with improving profitability. Here’s a detailed breakdown of key metrics.
- Revenue Trend: Sales rose to ₹5,665 crores in FY 24 from ₹3,625 crores in FY 23, reflecting substantial growth year-over-year.
- Equity and Liabilities: The company’s equity capital remained at ₹16 crores in FY 24, with reserves increasing to ₹8,706 crores. Total liabilities reached ₹10,661 crores, up from ₹8,778 crores in FY 23.
- Profitability: Operating profit increased to ₹1,333 crores in FY 24 from ₹1,025 crores in FY 23, with an OPM of 22.85% compared to 26.51% in the previous year.
- Earnings per Share (EPS): The EPS slightly decreased to ₹46.9 in FY 24 from ₹47.54 in FY 23, reflecting minor adjustments in profitability.
- Return on Net Worth (RoNW): The return on net worth shows steady performance as reserves grow, enhancing the company’s ability to generate profit from equity.
- Financial Position: Total assets expanded to ₹10,661 crores in FY 24, compared to ₹8,778 crores in FY 23, driven by significant growth in current and non-current assets.
Gland Pharma Ltd Financial Analysis
| FY 24 | FY 23 | FY 22 | |
| Sales | 5,665 | 3,625 | 4,401 |
| Expenses | 4,332 | 2,600 | 2,891 |
| Operating Profit | 1,333 | 1,025 | 1,510 |
| OPM % | 22.85 | 26.51 | 32.65 |
| Other Income | 170 | 184 | 224 |
| EBITDA | 1,503 | 1,265 | 1,734 |
| Interest | 26 | 7 | 5 |
| Depreciation | 345 | 147 | 110 |
| Profit Before Tax | 1,133 | 1,055 | 1,619 |
| Tax % | 32 | 26 | 25 |
| Net Profit | 772 | 781 | 1,212 |
| EPS | 46.9 | 47.54 | 73.75 |
* Consolidated Figures in Rs. Crores
Gland Pharma Company Metrics
Gland Pharma Ltd’s company metrics include a market capitalization of ₹32,307.81 crores, a book value per share of ₹530 and a face value of ₹1. With a debt-to-equity ratio of 4.27, a return on equity of 9.26% and a 1.02% dividend yield, these figures highlight the company’s financial health.
Market Capitalization: The market capitalization of Gland Pharma Ltd represents the total value of its outstanding shares, amounting to ₹32,307.81 crore.
Book Value: The book value per share of Gland Pharma is ₹530, reflecting the value of the company’s net assets divided by its total outstanding shares.
Face Value: The face value of Gland Pharma’s shares is ₹1, representing the nominal value of its shares as shown on the share certificate.
Asset Turnover Ratio: The asset turnover ratio of 0.60 measures the company’s efficiency in generating revenue from its assets.
Total Debt: Gland Pharma Ltd’s total debt stands at ₹372.17 crore, indicating its short-term and long-term financial obligations.
Return on Equity (ROE): Gland Pharma has an ROE of 9.26%, demonstrating its profitability in generating returns from shareholders’ equity.
EBITDA (Q): The company’s quarterly EBITDA stands at ₹315.83 crore, reflecting its earnings before interest, taxes, depreciation and amortization.
Dividend Yield: The dividend yield of 1.02% indicates the annual dividend as a percentage of Gland Pharma’s current share price, providing insight into returns from dividends.
Gland Pharma Ltd Stock Performance
Gland Pharma Ltd shows a one-year return on investment (ROI) of 13.9%, but over the past three years, the ROI has decreased by -21.5%. This indicates a short-term gain but a longer-term decline in returns for investors.
| Period | Return on Investment (%) |
| 1 Year | 13.9 |
| 3 Years | -21.5 |
Example: If you had invested ₹1,000 in Gland Pharma Ltd:
1 year ago, your investment would be worth ₹1,139.
3 years ago, your investment would have decreased to ₹785.
Gland Pharma Peer Comparison
Gland Pharma Ltd, with a current market cap of ₹30,617.47 crore, has a P/E ratio of 42.4 and a return on equity (ROE) of 9.26%. In comparison, Torrent Pharma leads with an ROE of 24.23%, while Marksans Pharma shows the highest one-year return at 192.17%.
| Name | CMP Rs. | Mar Cap Rs.Cr. | P/E | ROE % | EPS 12M Rs. | 1Yr return % | ROCE % | Div Yld % |
| Torrent Pharma. | 3428.05 | 115885.36 | 69.26 | 24.23 | 51.27 | 87.06 | 23.16 | 0.82 |
| Ajanta Pharma | 3238.35 | 40471.62 | 47.4 | 23.23 | 67.97 | 92.68 | 31.6 | 1.11 |
| Gland Pharma | 1857.85 | 30617.47 | 42.4 | 9.26 | 43.84 | 13.93 | 13.58 | 1.08 |
| ERIS Lifescience | 1284.5 | 17430.15 | 46.12 | 16.28 | 27.96 | 57.35 | 11.27 | 0.57 |
| Caplin Point Lab | 1956.25 | 14871.32 | 31.16 | 24.23 | 62.88 | 92.98 | 26.46 | 0.26 |
| Marksans Pharma | 309.85 | 14043.1 | 42.19 | 16.46 | 7.37 | 192.17 | 20.61 | 0.19 |
| Shilpa Medicare | 843.9 | 8264.93 | 201.24 | 1.71 | 4.97 | 139.37 | 5.25 | 0 |
Gland Pharma Limited Shareholding Pattern
Gland Pharma Ltd’s shareholding pattern as of June 2024 shows that promoters hold 51.83%, a decrease from 57.86% in March and December 2023. Foreign Institutional Investors (FIIs) increased their stake to 6.88%, while Domestic Institutional Investors (DIIs) now hold 32.83%. Retail investors hold 8.46%.
| All values in % | Jun-24 | Mar-24 | Dec-23 |
| Promotersinsight-icon | 51.83 | 57.86 | 57.86 |
| FII | 6.88 | 3.59 | 4.05 |
| DII | 32.83 | 25.23 | 24.17 |
| Retail & others | 8.46 | 13.32 | 13.93 |
Gland Pharma History
Gland Pharma Ltd, an India-based company, focuses on generic injectables across therapeutic categories such as oncology, ophthalmology and sterile injectables. The company offers contract development, technology transfer and manufacturing of complex injectables. Their products include Heparin Sodium and Enoxaparin Sodium.
Gland Pharma provides solutions across various delivery systems like liquid vials, lyophilized vials, pre-filled syringes and more. Key therapeutic categories include Anti-Malarials, Cardiac, Gastrointestinal and more, catering to markets in the United States, Europe and beyond.
The company is recognized for offering a broad range of molecules, serving various markets through its extensive distribution channels globally. Its emphasis on innovative injectables helps it maintain a competitive edge.
How To Invest In Gland Pharma Ltd Share?
To invest in Gland Pharma Ltd shares, you can use a broker. First, open a Demat account with Alice Blue. Once your account is active, you can place orders to buy or sell Gland Pharma shares directly on the platform.
Investing through brokers involves analyzing market trends and share price movements. Use technical and fundamental analysis to make informed decisions. Broker’s trading tools provide you with real-time data to make effective investment choices.
After purchasing Gland Pharma shares, monitor your investment regularly. Alice Blue provides insights and reports to track the company’s performance, helping you optimize your investment strategy.
Gland Pharma Limited Fundamental Analysis – FAQs
Fundamental Analysis of Gland Pharma Ltd reflects its financial status with a market cap of ₹32,307.81 crores, a P/E ratio of 42.4, a debt-to-equity ratio of 4.27 and a return on equity of 9.26%, indicating its current market position.
Gland Pharma Ltd has a market capitalization of ₹32,307.81 crores. This figure represents the total market value of the company’s outstanding shares, reflecting its position in the stock market and investor perception of the company’s value.
Gland Pharma Ltd is a pharmaceutical company based in India, specializing in generic injectable products. It operates in sterile injectables, oncology and ophthalmology sectors, providing contract development, dossier preparation and manufacturing services for various delivery systems across global markets.
Gland Pharma Ltd is owned by various institutional and retail investors. The company is publicly traded and its ownership is divided among promoters, foreign institutional investors (FII), domestic institutional investors (DII) and retail shareholders, reflecting a diversified ownership structure.
The main shareholders of Gland Pharma Ltd include institutional investors, FIIs, DIIs and promoters. These major stakeholders hold significant portions of the company’s shares, impacting its market movements and decision-making processes through their substantial investments.
Gland Pharma Ltd operates in the pharmaceutical industry, with a focus on manufacturing generic injectable products. It is involved in sterile injectables, oncology treatments and ophthalmology solutions, providing both contract development and manufacturing services to global markets.
To invest in Gland Pharma Ltd shares, you can open a trading account with Alice Blue, a leading brokerage platform in India. Through Alice Blue, you can buy and sell Gland Pharma shares on Indian stock exchanges, leveraging their online tools and resources for easy transactions.
Gland Pharma Ltd, with a P/E ratio of 42.4, may be considered overvalued compared to industry peers with lower P/E ratios. However, its financial performance and market position should be further analyzed to determine the company’s true valuation in the long term.
We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.
Disclaimer: The above article is written for educational purposes and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
